Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

We previously identified a chemotherapy-induced paracrine inflammatory loop that paradoxically mitigates the anti-tumor effect of chemotherapy and triggers metastatic propagation in breast and lung cancer models. Therefore, we sought to further validate and translate these findings into patient care...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, Paul K., Luo, Jia, Ai, Ni, Kim, Rachel, Ahn, Linda, Biswas, Anup, Coker, Courtney, Ma, Wanchao, Wong, Phillip, Buonocore, Darren J., Lai, W. Victoria, Chaft, Jamie E., Acharyya, Swarnali, Massagué, Joan, Kris, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568581/
https://www.ncbi.nlm.nih.gov/pubmed/36241629
http://dx.doi.org/10.1038/s41467-022-33719-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568581/
https://www.ncbi.nlm.nih.gov/pubmed/36241629
http://dx.doi.org/10.1038/s41467-022-33719-6

Ejemplares similares